Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. on June 9, 2021, covering events occurring on June 7, 2021. The filing primarily addresses corporate governance changes, specifically the election of a new director to the Board of Directors.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figures disclosed relate to director compensation:
- Annual Cash Fees: $40,000 for board service plus $4,000 for committee service.
- Equity Grant: Nonqualified stock options to purchase 100,000 shares of common stock.
Material Changes
The material change reported is the appointment of Evert B. Schimmelpennink as a Class I Director, effective June 7, 2021. He was also appointed to the Nominating and Corporate Governance Committee. His term continues until his successor is elected or until earlier resignation/removal.
Outlook, Risks, and Management Commentary
Management highlighted Mr. Schimmelpennink's qualifications, noting nearly 25 years of biotech and pharmaceutical experience. His background includes serving as CEO of Pfenex Inc. (leading it to FDA approval and acquisition) and Alvotech. The filing notes no family relationships or material interests in transactions requiring disclosure under Item 404(a). No specific risks, contingencies, or unusual items were disclosed in this report.
Investor Verification Checklist
- Verify the vesting schedule details for the 100,000 stock options granted to Mr. Schimmelpennink (36-month monthly installments).
- Confirm the total number of outstanding shares and the impact of this option grant on potential dilution.
- Review the attached Director Offer Letter (Exhibit 10.1) for additional terms not summarized in the 8-K.
- Check the Company's 2021 Annual Meeting proxy statement for the upcoming election of Class I Directors.